MX2009000763A - Derivados ciclicos como moduladores de la actividad del receptor de quimiocina. - Google Patents

Derivados ciclicos como moduladores de la actividad del receptor de quimiocina.

Info

Publication number
MX2009000763A
MX2009000763A MX2009000763A MX2009000763A MX2009000763A MX 2009000763 A MX2009000763 A MX 2009000763A MX 2009000763 A MX2009000763 A MX 2009000763A MX 2009000763 A MX2009000763 A MX 2009000763A MX 2009000763 A MX2009000763 A MX 2009000763A
Authority
MX
Mexico
Prior art keywords
modulators
chemokine receptor
receptor activity
cyclic derivatives
methods
Prior art date
Application number
MX2009000763A
Other languages
English (en)
Inventor
Soo S Ko
John Hynes
Percy H Carter
Robert J Cherney
Michael G Yang
Anurag Srivastava
Zili Xiao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2009000763A publication Critical patent/MX2009000763A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Esta invención se refiere generalmente a moduladores de la actividad del receptor de quimiocina que tiene una combinación inesperada de propiedades farmacológicas deseables. Las composiciones farmacéuticas que contienen el mismo, y métodos de uso del mismo como agentes para el tratamiento y prevención de enfermedades inflamatorias, enfermedades alérgicas, autoinmunitarias, metabólicas, cáncer y/o cardiovasculares, particularmente diabetes, enfermedad de Crohn, ateroesclerosis, y esclerosis múltiple, junto con métodos para preparar compuestos e intermediarios de los mismos. Los metabolitos de compuestos activos, composiciones farmacéuticas y uso de los mismo también se proporcionan en la presente.
MX2009000763A 2006-07-28 2007-07-26 Derivados ciclicos como moduladores de la actividad del receptor de quimiocina. MX2009000763A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83423506P 2006-07-28 2006-07-28
US89602607P 2007-03-21 2007-03-21
US11/782,810 US7687508B2 (en) 2006-07-28 2007-07-25 Cyclic derivatives as modulators of chemokine receptor activity
PCT/US2007/074378 WO2008014361A2 (en) 2006-07-28 2007-07-26 Cyclic derivatives as modulators of chemokine receptor activity

Publications (1)

Publication Number Publication Date
MX2009000763A true MX2009000763A (es) 2009-01-28

Family

ID=38870321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000763A MX2009000763A (es) 2006-07-28 2007-07-26 Derivados ciclicos como moduladores de la actividad del receptor de quimiocina.

Country Status (21)

Country Link
US (1) US7687508B2 (es)
EP (1) EP2049519B9 (es)
JP (1) JP5180961B2 (es)
KR (1) KR20090051061A (es)
CN (1) CN101568532A (es)
AR (1) AR062112A1 (es)
AT (1) ATE467625T1 (es)
AU (1) AU2007279236A1 (es)
CY (1) CY1110733T1 (es)
DE (1) DE602007006505D1 (es)
DK (1) DK2049519T3 (es)
ES (1) ES2346100T3 (es)
HR (1) HRP20100338T1 (es)
MX (1) MX2009000763A (es)
NO (1) NO20090205L (es)
PE (1) PE20081308A1 (es)
PL (1) PL2049519T3 (es)
PT (1) PT2049519E (es)
SI (1) SI2049519T1 (es)
TW (1) TW200813027A (es)
WO (1) WO2008014361A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629351B2 (en) * 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
WO2016010130A1 (ja) * 2014-07-17 2016-01-21 参天製薬株式会社 後眼部疾患の予防または治療剤
WO2023017483A1 (en) * 2021-08-13 2023-02-16 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for ccr2-expressing cells
JP2024529126A (ja) * 2021-08-13 2024-08-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 細胞傷害性標的キメラ
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
CN115677728A (zh) * 2022-11-02 2023-02-03 成都科岭源医药技术有限公司 一种海鞘素类化合物中间体的制备方法
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6383082A (ja) 1986-09-26 1988-04-13 Takeda Chem Ind Ltd テトラヒドロフランカルボン酸誘導体の製造法
EP0550924A1 (en) 1991-12-16 1993-07-14 Merck & Co. Inc. 2-Pyrrolidinone derivatives as HIV protease inhibitors
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6054579A (en) 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
ATE346050T1 (de) 1998-01-27 2006-12-15 Aventis Pharma Inc Substituierte oxoazaheterocyclyl faktor xa hemmer
IL137571A0 (en) 1998-01-29 2001-07-24 Aventis Pharm Prod Inc Method for preparing an n-[(aliphatic or aromatic)carboxyl]-2-aminoacetamide compound and a cyclyzed compound
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
AU7354900A (en) 1999-09-09 2001-04-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
AR035773A1 (es) 2000-12-20 2004-07-14 Bristol Myers Squibb Pharma Co Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina
CA2432908A1 (en) 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Company Diamines as modulators of chemokine receptor activity
DE60209471D1 (de) 2001-03-29 2006-04-27 Topo Target As Copenhagen Koeb Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
GB0114867D0 (en) 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
DE10135043A1 (de) 2001-07-11 2003-01-30 Bayer Cropscience Gmbh Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US7338975B2 (en) 2003-02-12 2008-03-04 Bristol-Myers Squibb Co. Lactams as modulators of chemokine receptor activity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
WO2004110376A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Ccr-2 antagonists for treatment of neuropathic pain
US7863317B2 (en) 2003-08-21 2011-01-04 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US20050043392A1 (en) 2003-08-21 2005-02-24 Carter Percy H. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
RU2007103332A (ru) 2004-07-30 2008-08-10 Пфайзер Продактс Инк. (Us) Способы лечения опосредуемых ccr2 заболеваний или нарушений
CA2582225A1 (en) 2004-09-28 2006-04-06 Mingde Xia Substituted dipiperdine ccr2 antagonists
US7629351B2 (en) * 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) * 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process

Also Published As

Publication number Publication date
CN101568532A (zh) 2009-10-28
TW200813027A (en) 2008-03-16
JP2009544757A (ja) 2009-12-17
PT2049519E (pt) 2010-08-18
PE20081308A1 (es) 2008-09-17
SI2049519T1 (sl) 2010-08-31
US7687508B2 (en) 2010-03-30
HRP20100338T1 (hr) 2010-07-31
US20080027080A1 (en) 2008-01-31
PL2049519T3 (pl) 2010-10-29
DK2049519T3 (da) 2010-09-13
AU2007279236A1 (en) 2008-01-31
ES2346100T3 (es) 2010-10-08
WO2008014361A2 (en) 2008-01-31
AR062112A1 (es) 2008-10-15
WO2008014361A3 (en) 2008-03-06
DE602007006505D1 (de) 2010-06-24
JP5180961B2 (ja) 2013-04-10
EP2049519B9 (en) 2010-12-29
EP2049519B1 (en) 2010-05-12
NO20090205L (no) 2009-02-26
KR20090051061A (ko) 2009-05-20
ATE467625T1 (de) 2010-05-15
EP2049519A2 (en) 2009-04-22
CY1110733T1 (el) 2015-06-10

Similar Documents

Publication Publication Date Title
MX2009000763A (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina.
GEP20094844B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2009106980A3 (en) Indazole derivatives
GEP20094843B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TW200621763A (en) Lactam compounds and their use as pharmaceuticals
WO2009069032A3 (en) Novel glucocorticoid receptor agonists
MA29088B1 (fr) Composes d'indazole-carboxamide.
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TW200626156A (en) Amido compounds and their use as pharmaceuticals
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
MX2010009462A (es) Derivados de indazol.
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
DE602007007934D1 (en) Imidazoazephinonverbindungen
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
TW200734335A (en) Compounds

Legal Events

Date Code Title Description
FG Grant or registration